ad best idea list
ad best idea list declin stock price follow januari ep releas
confer call upgrad share outperform neutral order growth surpass estim
last quarter due easi prior-year comp sequenti commun growth octob anticip
double-digit percentag order growth achiev remaind tol profit ramp
via two price increas announc alreadi potenti come home sell
close start averag higher gross margin close
produc y/i ep growth anoth catalyst share repurchas repurchas float januari
manag indic call could activ buyer stock current level valuat
perspect share trade ep compar group averag price-to-book
perspect trade price/tang book multipl versu group
wedbush equiti research depart focus deliv alpha within consum fig healthcar tmt
vertic best idea list compris highest rate equiti chosen analyst vet invest
committe manag risk avoid thesi creep employ automat sale rule stock move rel
basi versu averag move russel
upgrad outperform fed eas agency-focus mreit
rate substanti shape yield curv market react fulli fed cut
decemb perfect correl drop t-rate valu agenc
expect agnc book valu hold steadi improv invest margin like near
term remain high enough support compani current dividend equat per quarter get
complex one stock follow actual benefit disrupt marketplac
ps essenti credit risk
wedbush secur seek busi compani cover
research report thu investor awar firm may
conflict interest could affect object report investor
consid report singl factor make invest decis
pleas see page report analyst certif import
downgrad neutral boxr get
wedbush view discontinu compani lead program last umrx program
antibody-coupl cell receptor actr platform umrx devot effort toward develop
umrx expect file ind late year compani trim workforc
focu resourc sole boxr program umrx plan provid detail financi implic
restructur later month compani result given reset timelin reach market
long journey ahead downgrad neutral outperform near-term catalyst
long-term bolt-on chimer receptor boxr platform aim enhanc intrins cell function maintain
durabl tumor microenviron tme could show efficaci solid tumor cell design target
tumor cell bolt-on glutam oxaloacet transaminas enzym improv
metabol tme data last year meet encourag show superior antitumor
activ parent car-t therapi tme-lik condit car-resist mous xenograft model see note
incorpor valuat model opportun end-of-the-lin hepatocellular carcinoma
cancer associ high express
reduc ep estim bank reflect bp rate cut fed yesterday
region mid-cap bank lower ep estim monday note question
fed cut rate mani rate cut assum bp rate cut model april
incorpor yesterday bp rate cut assum addit rate cut year next forecast howev
report tabl gaug potenti impact ep fed cut addit bp assum juli would decreas
ep estim anoth region mid-cap bank believ bank
aggress pass yesterday bp rate cut depositor number bank face challeng pass
addit bp rate cut depositor median interest bear deposit cost region
bank mid-cap bank
fed realli avert recess cut rate view fed rate cut fix dampen econom growth
real problem contain could end hurt consum spend except mortgag refi busi
invest view on-going spread could tip point throw us recess
howev proactiv fed help borrow manag debt lower payment fear fed may use much
need ammunit prematur given economi perform well unemploy low busi
gener good financi posit happen economi goe recess fed number one tool
combat downturn unavail
select recommend given difficult backdrop top pick region rf
mid-cap pb ax remain cautiou asset sensit name
remain outperform rate share new target partner increas restor total enrol
shift random scheme parkinson diseas gene therapi studi overal await
addit updat time enrol complet see modif like facilit recruit
spoke manag ind file time indic updat look ahead detail phase vy-
aadc extens studi data repres meaning catalyst provid visibl respons
durabl amidst recent sector pullback see share offer attract risk/reward current level net cash
collabor revenu provid downsid protect target move extend vy-
launch time year
calm storm unev report ahead vy-aadc data report total revenu
beat consensu ws estim ep compani report also beat consensu
ws estim report cash/equival also consist previous guid
rang manag anticip exit cash/equival rang
pipelin updat vy-aadc notabl increment parkinson diseas pd huntington
vy-aadc overal indic vy-aadc data updat provid better insight
durabl respons manag provid specif clariti statist power assumpt
revis studi indic design well power chang made primari
endpoint manag updat time recruit restart although remain track
 new observ studi ind file updat plan initi observ hd studi
subject elig roll expect phase clinic trial howev compani plan
provid updat regard ind plan spoke compani note observ
studi ind file link see littl risk ind progress
continu hold posit outlook ytd basi share under-perform biotech sector vs
nbi nevertheless see attract risk/reward term downsid see current net cash
collabor revenu provid downsid protect think upcom long-term phase vy-aadc data provid
catalyst share work higher better inform durabl treatment push
estim one year continu leav major pipelin upsid like setup share
blood special juic
wedbush view report earn compani present multipl updat pipelin recent
tct meet orlando fl see note look forward mgta advanc ph studi
path toward ind file antibodi drug candid
push ph program
ph studi complet enrol compani cell therapi product intend inherit
metabol diseas cald mld gld ph studi updat tct show two treat cald pt
gadolinium resolut day persist year along stabl score nf three pt
show stabl blood leukocyt idua activ posit reduct urin biomark level one year
pt amen treatment paradigm compar histor control median number day neutropenia
median day platelet recoveri median day hospit day target enrol studi patient
compani anticip complet year see potenti program move quickli pivot studi
compani continu engag regul design
ph studi take shape compani cell mobil program recent complet
enrol ph studi healthi volunt recent updat program also present tct
show one day mobil high qualiti stem cell part studi demonstr pt surpass
clinic threshold success transplant singl apheresi collect engraft stem cell two
subject mice higher multilineag engraft compar g-csf-mobil counterpart plan open
multipl ph trial year allogen autolog transplant set evalu mobil collect
engraft cell transplant anticip rel quick enrol readout given natur
studi
manufactur scale ind approach amanitin-bas candid disclos
earli year intend condit regimen stem cell transplant gene therapi aim
clinic-readi scale manufactur continu ind-en studi year
encourag data origin present show success transplant autolog gene-modifi cell
nhp singl dose look forward advanc program
move toward ind preclin data immun system reset program origin present
acr last novemb show condit subsequ transplant mice effect reset immun
system result compar soc efficaci use model multipl sclerosi inflammatori arthriti system
sclerosi continu watch program move closer ind file
cfo sharp bid adieu search commenc
wedbush view remain outperform rate move unexpect long-tim cfo shalini sharp
announc plan exit begin sept cfo sharp hold lengthi tenur help shape
financi direct compani broad rang asset span differ stage development/mod
global commerci organ multipl collabor relationship envis mani suitor seek
fill role put recent market turbul asid continu hold posit bia share see
compani well posit multipl gene therapi data readout near pdufa juli
cfo sharp announc departur market close tuesday cfo shalini sharp announc plan leav
effect sept news expect cfo sharp compani sinc spoke
manag updat
readi make move cfo sharp one first hire found becam publicli
trade entiti time compani rapidli evolv start-up clinical-stag commerci entiti
rel brief timelin look ahead think natur point compani find successor
global commerci experi
search commenc indic team begin search replac candid effort like
concentr extern cfo sharp remain helm facilit transit septemb time frame
bottom line feel timelin leav ampl room incorpor successor limit disrupt
continu see posit setup year ahead share outperform nbi ytd basi
vs nbi despit tumultu market backdrop see strength share deriv larg part pipelin
effort gene therapi also monet crysvita ex-u right see link look ahead see sever
key catalyst help share maintain solid foot even risk-off environ first regulatori
front note two upcom pdufa crysvita june lc-faod juli second multipl gene therapi
catalyst track phase confirmatori cohort data prophylact steroid data
lastli pipelin program progress toward ind file angelman wilson diseas bottom line see
much excit cfo sharp leav big shoe fill leav point compani
good posit remain outperform rate
recent share pressur entir align potenti impact
estim potenti impact demand destruct logic impli primarili
franchis name within coverag univers rel insul
howev magnitud restaur share price declin sinc februari seem logic align
estim potenti impact
assum long-term driver littl impact impli recent contract valuat denominator-
driven word market bake declin ep expect across name rel
expect
case v-shape recoveri turn financi crisi imperfect context
review weak sale primarili due transitori pressur
report result beat ep sharpli miss comp comp miss buy side expect
primarili due unfavor winter weather span length azo quarter calendar shift
headwind slow start tax refund nonetheless comp market materi impact weather
adjust calendar shift materi slowdown report comp prior quarter believ
comp trend bounc sharpli start underli industri driver remain intact yet even commerci sale
growth return doubl digit y/i believ challeng drive comp
balanc fiscal year comparison toughen coronaviru add suppli demand risk see manag
point time commend manag cost reduc sg de-lever soft sale environ
also drive gross margin higher support ebit margin combin lower-than-expect tax rate share
repurchas increas ep y/i ahead consensu estim continu see
lsd-msd ebit grower limit comp upsid potenti keep us neutral lead us reduc price target
share pressur guidanc fall expect
report ep includ charg primarili relat integr trunk club debt
refinanc estim consensu prior guidanc revenu
consensu mm in-lin data forecast spike promot rack march preview
continu leav us cautious monitor promot activ channel quarter progress local
market strategi perform well fourth quarter net sale lift bp exist market
continu expand total citi expans overlap half sale includ philadelphia
washington boston seattl toronto market strategi gener grow traffic order pickup
market non-market store eager see engag uptick across new market
erik ceo pete serv presid inc chief brand offic
transit away co-presid titl board member seek re-elect size board
reduc term limit year continu model ep full year
model ep estim compar guidanc consensu see valu share
long-term deep valu investor drive valu time benefit compani local market
strategi uniqu limit distribut brand growth leverag owe power omnichannel
deliv above-consensu result ep compar estim consensu
guidanc revenu growth compstore best consensu growth compstore owe
higher traffic increas size averag basket howev higher distribut cost bp due unfavor
time packaway-rel expens higher wage hit along bp due pressur tariff off-set
bp lower fright occup lead hit gross margin compar consensu sg lever mainli
due lower incent bonu includ oper margin report in-lin consensu estim
manag guid above/below consensu guidanc guidanc versu
consensu lower ep estim
look beyond manag provid disappoint guidanc includ impact
ep project consensu revenu compar store sale
guid consensu evidenc forward-look search data februari adj r-squar f-stat signif
show revenu run street far oper margin guidanc also disappoint
manag point bp headwind last year blame tariff impact de-lever occup
expens model ep compar guidanc consensu model
ep compar guidanc consensu
share like oversold promo improv initi spark lt opportun
report ep ex-item versu consensu higher plan promot activ
order clear excess inventori evidenc bp year-over-year declin gross margin in-lin insight
promo tracker pre-announc core urban experienc challeng holiday season higher markdown led
lower margin posit women spring apparel receiv favor reaction na eu inde strong
start core accord proprietari promo tracker insight promo tracker show signific
improv core urban brand februari see remov sever free ship deal member
on-line day valentin day well lower discount home clearanc app offer anthropologi
continu see increment home furnitur sale messag februari sever free ship deal becam
access custom lower purchas limit see remov friend referr discount lower
clearanc toward end month encourag anthropologi custom respond well higher markdown rate
look manag encourag see current compstore trend msd posit retail segment gross margin guid
flat posit quarter compani see improv product perform lower overal markdown in-lin
observ promo tracker neg impact nuuli subscript program wholesal margin
point gross margin y/i dampen outlook compani guid sg fiscal year mainli
due increas incent comp versu prior year increment market expens support retail subscript
segment see guidanc prudent believ make right decis build subscript program
reward out-performance see upcom invest distribut facil eu na correct step achiev
long-term success model ep vs prior compar consensu model
ep vs prior compar consensu inventori close compar growth
net sale rate share neutral maintain price target repres ep estim
finish year model shift focu beyond
last night deliv strong finish beat street across board total revenu grow
year year driven mobil secur offer e-signatur solut acceler y/i note
guidanc slightli expect due model shift current take place
focu subscript thu caus slight headwind perpetu licens well hardwar revenu
point view pivot year transit year financi servic hardwar provid
limit modern softwar secur player offer extens authent fraud prevent solut
could major year success compani opinion believ time rip band-aid fulli
transit platform execut around softwar focu invest heavili softwar transit
develop tid platform focu cloud-first solut made signific invest realign
sale structur encourag subscript contract opinion ultim help provid cross sell
opportun especi mobil secur front compani continu expand mobil fraud prevent offer
nutshel believ core fundament market opportun remain rel healthi
runway ahead continu gain confid stori maintain neutral rate price target
takeaway manag meet
host sell-sid analyst roundtabl session yesterday ceo shar dubey cfo gari swidler svp ir
lanc barton manag stress continu new previou leadership ms dubey
work close previou ceo mandi ginsberg year expect ms dubey well posit execut
vision built ms ginsberg leadership overal strategi remain focu tinder monet
hing monet also build liquid us market follow broader intern roll-out long-term
growth asia better penetr categori accept specif product build-out like live video stream
event tangenti opportun like matrimoni date coach separ impact coronaviru still
earli tell remain balanc like smooth ceo transit intern monet opportun
greater degre challeng around increas monet vs sub growth local cannib therefor
remain neutral despit strong steadi vision manag
pleas see full note detail analysi
compani cover respect research analyst analyst certifi view express research report
accur reflect research analyst person view subject secur compani part
compens directli indirectli relat specif recommend view contain research report
outperform expect total return stock outperform rel median total return analyst analyst
team coverag univers next month
neutral expect total return stock perform in-lin median total return analyst analyst team
coverag univers next month
under-perform expect total return stock under-perform rel median total return analyst
analyst team coverag univers next month
invest rate base expect perform stock base anticip total return price target rel
stock analyst coverag univers analyst team coverag
march
march
distribut rate requir finra rule howev ws stock rate outperform neutral under-perform
close conform buy hold sell respect pleas note howev definit ws stock rate
rel basi
analyst respons prepar research report receiv compens base specif invest bank activ
analyst receiv compens base upon variou factor includ ws total revenu portion gener
ws invest bank activ
